Inventiva announces that FDA lifts target class clinical hold which allows long-term clinical studies with lanifibranor in NASH

by NASDAQ Market News May 23, 2019

NASDAQ Market News
Click here to email author

Repeat: Inventiva announces that FDA lifts target class clinical hold which allows long-term clinical studies with lanifibranor in NASH

Robust Clinical Data and Positive Customer Experience with T2Bacteria and T2Candida Panels Highlighted at Recent Medical Meetings

Ads